2020s
2025
- Jan.Merger and Spin-off of MediplaMaterials Co., Ltd.
- Jan.NH Investment & Securities selected as Lead Underwriter for IPO
- Jul.Final Marketing Authorization Approved for UK Tauro Kit 2% Inj. (Taurolidine)
2024
- Jul.Launch of Expanded Half-Kit Product (Sales team confirmation required)
- Oct.Participation in CPHI MILAN 2024 (Consider adding to corporate history)
- Oct.Certified as a Promising Small and Medium Enterprise by Gyeonggi Province
- Dec.Selected as an Excellent Employer by the City of Ansan
- Dec.Signed Co-Promotion Agreement for UK KIT with Kukje Pharma
2020
- Jan.Registration of Escitalopram Oxalate as Active Pharmaceutical Ingredient (DMF)
2010s
2018
- Aug.Purchased new manufacturing site to increase production capacity
- May.Completed DMF registration for Iomeprol(API) – First Generic API in Korea
- Apr.Completed production line separation (Cephalosporin Class)
2017
- Jan.Signed a Co-MKTG Alliance with Yungjin Pharmaceutical
2013
- Jul.Signed a Co-MKTG Alliance with Daewoong Pharmaceutical
2012
- Feb.Acquired U.S. patent for UK Injection Kit
2011
- Sep.Acquired Certificate of INNO-BIZ (Ministry of SMEs and Startups)
- May.Received grade “A” in technology appraisal of UK Injection Kit
(Korea Technology Finance Corporation)
- Apr.Added automated production lines for UK Kit Products by plant expansion
2010
- Dec.Completed automated production lines for UK Kit Products
2000s
2009
- Sep.Acquired Certificate of Venture Businesses (Korea Technology Finance Corporation)
2007
- Dec.Filed a patent application for UK Injection Kit under the PCT
2005
- Aug.Acquired BGMP certification (MFDS)
2004
- Jul.Began domestic sales
- Apr.Began foreign sales including Japan
- May.Acquired KGMP certification (MFDS)
2003
- May.Gained permits for pharmaceutical manufacturer
1990s
1997
- Jul.Completed Plant registration
1996
- Apr. Awarded for the export of one million dollars (Korea International Trade Association)
1992
- Jul. Established UK CHEMIPHARM Co.